Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/10/08 05:51:53」(JST)

wiki en

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References[edit]

H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
Prous Science: Molecule of the Month November 2006

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 低ナトリウム血症の治療：抗利尿ホルモン不適合分泌（SIADH）症候群およびreset osmostat症候群 treatment of hyponatremia syndrome of inappropriate antidiuretic hormone secretion siadh and reset osmostat
2. 低ナトリウム血症の治療の概要 overview of the treatment of hyponatremia

English Journal

Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.

Ectopic ADH Syndrome Therapeutic Research Group, Yamaguchi K, Shijubo N, Kodama T, Mori K, Sugiura T, Kuriyama T, Kawahara M, Shinkai T, Iguchi H, Sakurai M.SourceOffice of the President, Shizuoka Cancer Center, Sunto-gun, Shizuoka 411-8777, Japan. k.yamaguchi@scchr.jp
Japanese journal of clinical oncology.Jpn J Clin Oncol.2011 Jan;41(1):148-52. Epub 2010 Nov 17.
Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard
PMID 21087977

[Vasopressin receptor antagonists: the vaptans].

Villabona C.SourceServicio de Endocrinologia y Nutricion, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.Endocrinol Nutr.2010 May;57 Suppl 2:41-52.
The non-peptide vasopressin antagonists (VPA), called vaptans, were developed in the 1990s to antagonize both the pressor and antidiuretic effects of vasopressin. There are three subtypes of VPA receptors: V1a, V1b and V2. V1a receptors are widely distributed in the body, mainly the blood vessels an
PMID 21130961

Related Pictures

★リンクテーブル★

リンク元	「モザバプタン」
拡張検索	「mozavaptan hydrochloride」

「モザバプタン」

Mozavaptan
Systematic (IUPAC) name
	N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
Clinical data
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Identifiers
CAS number	137975-06-5
ATC code	None
PubChem	CID 119369
ChemSpider	106618
UNII	17OJ42922Y
ChEMBL	CHEMBL420762
Chemical data
Formula	C27H29N3O2
Mol. mass	427.53 g/mol
	SMILES CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C;
	InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) ; Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N ;
(what is this?) (verify);